Clinical Trial

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Study acronym: Pearl-2
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped chest area). KB304 is an investigational gene therapy that delivers functional, full-length human collagen (COL3) and elastin (tropoelastin) to the skin through small injections using the Sponsor's genetically engineered Herpes Simplex Virus (HSV-1) vector. The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inactive group).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-05; most recent amendment 2025-05-08.
Status change: Recruiting → Active, Not Recruiting 2025-05-08
Trial Details
NCT Number NCT06724900
Lead Sponsor Krystal Biotech, Inc.
Conditions Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles
Enrollment 19 participants
Start Date 2024-11-20
Primary Completion 2025-07 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-13